masitinib

AssetAlso AB1010

Tyrosine kinase inhibitor targeting c-Kit, PDGFR, and Lyn to modulate mast cells and microglia.

Stage: Phase 3
Modality: Small molecule
Target: Inflammation; 27
Indications: 32
Trials: 1
Developer

Indications

27

Alzheimer's disease
Phase 3, Completed, NCT01872598, clinicaltrials.gov, 8 Oct 2026
Amyotrophic lateral sclerosis
Phase 3, Not yet recruiting, NCT07174492, clinicaltrials.gov, 8 Oct 2026
Asthma
Phase 3, Completed, NCT03771040, clinicaltrials.gov, 8 Oct 2026

24 more

In the full profile

Targets and what it contains7
Owner and partners1
Trials32
Evidence for its targets5
Competitors12
Aging relevance1
Signals3

Every asset’s record: target, stage, trials and the evidence behind it.

Updated 8 Oct 2026, 29 sources